Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.62 |
| ▸ | HTR2C | P28335 | 8/20 | 0.60 |
| ▸ | QDPR | P09417 | 3/20 | 0.53 |
| ▸ | KMO | O15229 | 1/20 | 0.49 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.48 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31705007 | 0.83 | HTR2C (0.54) | SIGMAR1HTR2CQDPR | |
| SCHEMBL3168588 | 0.83 | HTR2C (0.54) | SIGMAR1HTR2CQDPR | |
| SCHEMBL4746022 | 0.82 | QDPR (0.62) | SIGMAR1HTR2CQDPRFTOP2RY14 | |
| Hydrochloric Acid SCHEMBL30946041 | 0.82 | HTR2C (0.55) | SIGMAR1HTR2CQDPRFTO | |
| Trifluoroacetic Acid SCHEMBL1873949 | 0.80 | HTR2C (0.53) | SIGMAR1HTR2CQDPRFTOP2RY14 | |
| Hydrochloric Acid SCHEMBL1868518 | 0.79 | HTR2C (0.58) | SIGMAR1HTR2CQDPR | |
| SCHEMBL4791120 | 0.79 | SIGMAR1 (0.79) | SIGMAR1HTR2CQDPR | |
| SCHEMBL29522119 | 0.79 | SIGMAR1 (0.49) | SIGMAR1HTR2CQDPRFTOP2RY14 | |
| SCHEMBL415545 | 0.78 | SIGMAR1 (1.00) | SIGMAR1HTR2CQDPR | |
| SCHEMBL21228136 | 0.78 | HTR2C (0.66) | SIGMAR1HTR2CQDPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700591-B2 | Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors | MERCK & CO., INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700591-B2 | Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors | MERCK & CO., INC. (US) | 2010-04-20 | — | — | US | disclosed |
| EP-1615699-B1 | BENZOXAZINYL-AMIDOCYCLOPENTYL-HETEROCYCLIC MODULATORS OF CHEMOKINE RECEPTORS | MERCK SHARP & DOHME (US) | 2010-03-24 | — | — | EP | disclosed |
| US-20070238723-A1 | Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors | GOBLE STEPHEN D | 2007-10-11 | — | — | US | disclosed |
| US-20070238723-A1 | Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors | GOBLE STEPHEN D | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238723-A1 | Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors | CCR1, CCR2, CCRL2 | SIGMAR1 2453/4885HTR2C 306/4885QDPR 2540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.